BMYB34:BVMF
Bristol-Myers Squibb Company BDR
331,90 BRL
arrow_upward
+0,65%(+2,15) 1D
30-сен., 11:31:25 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMYB34...
Mkt. cap
121,70 млд
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 BRL
52-wk low
221,72 BRL
Shares outstanding
2,04 млд
No. of employees
32 миң
Mkt. cap
121,70 млд
Avg. vol.
3,00
Volume
0,00
52-wk high
347,15 BRL
52-wk low
221,72 BRL
Shares outstanding
2,04 млд
No. of employees
32 миң
News stories
From web sources and news partners
The Motley Fool
·
59 мүнөт мурун
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AD HOC NEWS
·
7 саат мурун
Bristol Myers Squibb stock trades at EUR 53.13 with USD 121.5 billion market cap
MarketBeat
·
8 саат мурун
Bristol Myers Squibb Company $BMY Stock Sold by Quintet Private Bank Europe S.A.
Investing.com
·
13 саат мурун
Cantor Fitzgerald lowers Bristol-Myers Squibb price target to $53
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32,5 миң
Founded1887
HeadquartersНью-Йорк, Нью Йорк, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitebms.com